Cure My Disease

Don't miss your cure!

 Log in / Sign up

Dialysis filter showdown: could the right membrane tame inflammation?

NCT ID NCT07682701

Knowledge-focused Sponsor: Universitair Ziekenhuis Brussel Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time

Summary

This study tests whether the type of filter (membrane) used during hemodialysis changes how immune cells and clotting factors react. Ten adults on long-term dialysis will try three different membranes over one week, with blood samples taken during each session. The goal is to see if any membrane causes less immune activation and clotting, which could lead to safer dialysis.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
dialyzer membrane (polysulfone, asymmetric triacetate, or polymethyl methacrylate)
What this could lead to
If one membrane type triggers less immune activation and clotting, it could point toward safer dialysis for people with kidney failure.
What could go wrong
This is a very small, short-term study (10 people, 1 week) looking at lab markers, not patient outcomes. Results may not change practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

10 people

The number who actually took part.

Started

Apr 2026

Expected to finish

Oct 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Dialysis vintage ≥ 3 months * Treatment schedule of 3x4 hours weekly * well functioning dual lumen vascular access * Treatment with ASA 80-100mg daily * Patients able and agree to provide signed informed consent Exclusion Criteria: * Known vascular access dysfunction defined by FOR CATHETER ACCESS: high dose urokinase use within 4 weeks prior to study participation, planned catheter opacification, Qb \<250mL/min within the 2 weeks prior to study participation FOR AV ACCESS: planned AV access intervention, recent AV access intervention within 4 weeks prior to study participation, known AV access dysfunction * Known active malignancy and/or active autoimmune disease * Known clotting/bleeding disorders * Current treatment with immunosuppressive medication * Current treatment with P2Y12 receptor antagonists (including clopidogrel, prasugrel, ticlodipine, cangrelor, ticagrelor), epoprostenol and glycoproteine IIb/IIIa receptor antagonists (tirofiban) * Current treatment with oral anticoagulation maintenance therapy, including vitamin K antagonists or direct oral anticoagulants * Current treatment with low molecular weight heparins (LMWH), heparinoids, bivalirudin, fondaparinux, protein C, or antithrombin. * Active infection and/or ongoing systemic antimicrobial treatment. * Hospitalized patients * Patients treated with heparin-free hemodialysis * Recent (\<1 week) platelet transfusion or packed cells transfusion * Patients receiving intradialytic TPN * Patients requiring intravenous iron administration during dialysis (EPO or Parsabiv administration will be postponed until after disconnection from the dialysis circuit and after T240 blood sampling). * Patients with cytopenia affecting either white blood cells (WBC \< 4x10³/mm³) or platelets defined as (platelet counts \<100x10³/mm³) * Patients known to have had allergic reactions to PS, PMMA or ATA dialyzer

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for End-stage renal disease (ESRD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease end stage renal failure Thromboinflammation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

End-stage renal disease (ESRD) Hemodialysis Hemodialysis treatment Thromboinflammation

Contacts and locations

Locations

  • Universitair Ziekenhuis Brussel

    Brussels, 1090, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.